Inclusion Criteria:

        This study will enroll 28 evaluable patients. Fourteen (+/- 2) patients will be required
        tto be on dialysis and 14 (+/- 2) patients will not be on dialysis.

          -  Newly diagnosed multiple myeloma diagnosis according to IMWG criteria. Patients
             eligible for autologous stem cell transplant may be enrolled if the intent is to
             proceed to transplant after 4 or more cycles of study treatment.

          -  Severe renal impairment (eGFR < 30ml/min/1.73m^2 using the MDRD calculator) or on
             dialysis. The value at screening confirms eligibility (if eGFR improves prior to
             enrollment, this does not render a patient ineligible) The renal impairment may be
             acute or chronic and may be related to the underlying myeloma (e.g. multiple myeloma
             (MM) cast nephropathy, monoclonal immunoglobulin deposition disease [MIDD], myeloma
             cell infiltration) or another cause (e.g. diabetes, hypertension), however the
             acuity/chronicity and the underlying cause should be documented clearly. Those who
             have acute kidney injury from hypercalcemia should receive intravenous hydration and
             calcium-lowering therapy to see if this renal impairment is reversible.

          -  At least 18 years of age.

          -  ECOG performance status ≤ 2

          -  Bone marrow and organ function as defined below:

               -  Absolute neutrophil count ≥ 1,000/mm3 (growth factor to achieve this level is
                  permissible)

               -  Platelets ≥ 50,000/mm3 (transfusion to achieve this level is permissible)

               -  Bilirubin ≤ 2 mg/dL

               -  AST(SGOT)/ALT(SGPT) ≤ 3.5 x institutional upper limit of normal (IULN)

          -  The effects of isatuximab and bortezomib on the developing human fetus are unknown.
             For this reason, women of childbearing potential must agree to use adequate
             contraception (hormonal or barrier method of birth control, abstinence) prior to study
             entry, for the duration of study participation, and for 5 months after discontinuation
             of study treatment. Should a woman become pregnant or suspect she is pregnant while
             participating in this study, she must inform her treating physician immediately. Men
             treated or enrolled on this protocol must also agree to use adequate contraception
             prior to the study, for the duration of the study, and 5 months after completion of
             the study

          -  Ability to understand and willingness to sign an IRB approved written informed consent
             document (or that of legally authorized representative, if applicable).

        Exclusion Criteria:

          -  Concomitant use of other anti-neoplastic medications or radiotherapy (except for
             localized disease). Note: Participants are permitted to have received one dose of
             bortezomib or up to 80 mg of dexamethasone (or equivalent) prior to study treatment
             initiation if deemed clinically necessary for disease control.

          -  Currently receiving any other investigational agents.

          -  Evidence of myeloma within the CNS

          -  Presence of amyloidosis without concomitant multiple myeloma. Patients with
             concomitant amyloidosis and multiple myeloma are eligible.

          -  Prior refractoriness, intolerance or hypersensitivity to bortezomib.

          -  Prior treatment with an anti-CD38 monoclonal antibody.

          -  A history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to isatuximab, bortezomib, or dexamethasone or other agents used
             in the study.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac
             arrhythmia.

          -  Pregnant and/or breastfeeding. Women of childbearing potential must have a negative
             pregnancy test within 14 days of study entry.

          -  Active acute or chronic hepatitis B viral infection.

               -  Screening with serological tests for HBV with surface antigen and antibody (HBsAg
                  and HBsAb) and HBV total core antibody (HBcAb IgG and IgM), and screening for HCV
                  (HCV Ab and HCV RNA level) are required to have been performed within 1 year of
                  screening, or should otherwise be performed as part of screening.

               -  Patients with uncontrolled or active HBV infection (patients with positive HBsAg
                  and/or HBV DNA), as well as patients with active HCV infection (positive HCV RNA
                  and negative anti-HCV) are not eligible

               -  In case HBcAb are positive, HBV DNA testing by polymerase chain reaction will
                  also be done at baseline. For patients with positive anti-HBc IgG, negative HBsAg
                  and undetectable (under limit of quantification) HBV DNA at study entry (HBV
                  carriers: past resolved infection, resolving acute infection or receiving
                  antiviral treatment with controlled infection), specialist advice may be
                  requested, close monitoring of viral reactivation throughout and following the
                  end of study treatment should be proposed (alanine aminotransferase, aspartate
                  aminotransferase, and HBV DNA at least every 3 months, up to 6 months after
                  treatment discontinuation or initiation of further anticancer therapy.

          -  Patients with HIV are eligible unless their CD4+ T-cell counts are < 350 cells/mcL or
             they have a history of AIDS-defining opportunistic infection within the 12 months
             prior to registration. Concurrent treatment with effective ART according to DHHS
             treatment guidelines is recommended.

          -  Baseline Grade 2 or higher peripheral neuropathy